• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CDXC

CDXC

ChromaDex Corporation

NASDAQHealthcareBiotechnologyUS

USD7.87

-0.07 (-0.88%)

Company Profile

CEO

Frank Louis Jaksch Jr.

IPO Date

2008-06-25

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$7.91

Prev. Close

$7.94

Day Low

$7.75

Day High

$7.92

52W Low

$2.31

52W High

$9.18

Market Cap

$0.61B

Volume

0.54M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

36.4%

Avg Negative

2.8%

Avg Neutral

60.8%

News Feed

ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/3/2021·↓ negative

ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Business Wire·7/20/2021·↓ negative

ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)

Business Wire·6/16/2021·↑ positive

Why ChromaDex Stock Is Jumping Today

The Motley Fool·6/7/2021·↑ positive

CDXC Stock Price: Over 10% Increase Pre-Market Explanation

Pulse2·6/7/2021·↑ positive

ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States

Business Wire·6/7/2021·↑ positive

ChromaDex (CDXC) CEO Robert Fried on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/8/2021·↓ negative

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

ChromaDex and Ro Partner for New Product Development

Business Wire·5/4/2021·↑ positive

ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

Business Wire·4/29/2021·↓ negative